Andere Sprachen Medivir AB

Aktien

A3EFZT

SE0020181014

MVIR B

Verzögert Nasdaq Stockholm Andere Börsenplätze 17:23:22 29.04.2024			% 5 Tage	% 1. Jan.
3,19 ^SEK	-1,54 %		+11,93 %	+11,93 %

22.02.	Medivir stellt auf dem Easl Liver Cancer Summit Daten vor, die die Kombination Fostrox/Lenvima bei primärem Leberkrebs stärken	CI
15.02.	Transcript : Medivir AB, Q4 2023 Earnings Call, Feb 15, 2024

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Medivir brings the Q1 webcast forward to 10 a.m. on April 30	11:09
Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI	10:01
BioStock: Medivir optimizes study design after meeting FDA	26.04.
Medivir Gets Two US FDA Designations for MIV-711	25.04.
Medivir : FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease	25.04.
FDA grants Medivir's MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease	25.04.
Medivir provides update from supportive Type C meeting with the FDA; preparations for enhanced phase 2b in HCC with fostrox + Lenvima continue	23.04.
BioStock: Medivir's partner makes clinical progress in veterinary project	19.04.
Medivir : The Board of Directors statement under Chapter 19 Section 22 of the Swedish Companies Act	16.04.
Medivir's partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701	15.04.
BioStock: Medivir continues to accelerate development with fostrox	12.04.
Medivir : The Nomination Committees proposal for the AGM	09.04.
Medivir to present at Investing in Oncology Forum on April 10	09.04.
Medivir : Corporate Governance Report	05.04.
Medivir 2023 Annual Report published	04.04.
Medivir : Notice of AGM 2024	04.04.
Notice of Annual General Meeting of Medivir AB (publ)	04.04.
Certain Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 21-MAR-2024.	21.03.
Medivir to present at Swiss Nordic Bio in Zürich on March 7	06.03.
Medivir to present at the Life Science Day in Gothenburg on March 6	04.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Medivir AB

Aktien

A3EFZT

SE0020181014

MVIR B

Andere Sprachen

Filter